

NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of:

Inventor(s): Solomon Assefa, Leslie A. Kolodziejski, Gale S. Petrich

For (title): ELECTRICALLY-ACTIVATED PHOTONIC CRYSTAL
MICROCAVITY LASER**1. Type of Application**

- ☒ Utility
☐ Design

2. Small Entity

- ☒ Yes
☐ No

3. Benefit of Prior U.S. Application(s) Under 35 U.S.C. §120

This application is a:

- ☐ Divisional
☐ Continuation
☐ Continuing Patent Application (CPA) under 37 C.F.R. §1.53(d)
☐ Continuation-in-part (CIP),

and hereby claims benefit under 35 U.S.C. §120 to the following applications:

SERIAL NUMBER	FILING DATE

4. Benefit of Non-U.S. Application Under 35 U.S.C. §119(a)-(d)

This application claims priority under 35 U.S.C. §119(a)-(d) to the following foreign application(s) and/or inventor certificate(s):

COUNTRY	APPLN. NUMBER	FILING DATE
None		

Certified copy(ies) of the application(s) and/or inventor certificate's from which priority is claimed:

- ☐ is(are) attached;
☐ will follow.

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on **November 25, 2003** in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number **EV303918210US** addressed to the: Mail Stop Patent Application, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Emily C. Porell
Emily C. Porell

5. **Benefit of Provisional Application Under 35 U.S.C. §119(e)**

This application claims priority to the following provisional application(s):

SERIAL NUMBER	FILING DATE
None	

6. **Papers Enclosed Which Are Required For Filing Date Under 37 C.F.R. §1.53**

18 Pages of Specification, including cover sheet, claims, and abstract

3 Sheets of Drawing

7. **Additional Papers Enclosed**

- ☐ Declaration and Power of Attorney
- ☐ Preliminary Amendment
- ☒ Information Disclosure Statement (37 CFR 1.98), Form PTO-1449 and a copy of each cited reference
- ☐ Assignment and Form PTO-1595
- ☐ Declaration of Biological Deposit
- ☐ Submission of "Sequence Listing" computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequences.
- ☐ Other _____

8. **Application Filing Fee Calculation**

A. ☒ Utility Application

FEE CALCULATION:

Total Claims: 72 - 20 = 52 × \$18 = \$ 936.00

Independent Claims: 4 - 3 = 1 × \$86 = \$86.00

Basic Fee: \$770.00

Multiple-Dependent-Claim Fee : \$

Total of the Above Calculations: \$1,792.00

- ☐ Amendment canceling extra claims enclosed.
- ☐ Amendment deleting multiple dependencies enclosed.
- ☐ Fee for extra claims is not being paid at this time.

B. ☐ Design application - \$320 \$

Application Filing Fee Sub-Total \$

C. ☒ Less 50% reduction for small entity..... \$896.00

D. ☐ Non-English Specification - \$130..... \$

TOTAL FILING FEE \$ 896.00

9. **Payment**

- ☒ Enclosed
- ☒ Check in the amount of the Total Filing Fee set forth above.
- ☐ Charge Account No. 19-0079 in the amount of Total Filing Fee set forth above. A duplicate of this transmittal is attached.
- ☐ Not Enclosed

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 and 1.17 that may be required by this paper or any paper filed in connection with this Patent Application, or refund any overpayment to our Deposit Order Account No. 19-0079.

Respectfully submitted,

Pat. Appl. Reg. No. 47,259

Matthew E. Connors

Reg. No. 33,298

Samuels, Gauthier & Stevens LLP

225 Franklin Street, Suite 3300

Boston, MA. 02110

(617) 426-9180, Ext. 112

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST AND CERTIFICATION UNDER 35 U.S.C. 122(b)(2)(B)(i)	First Named Inventor		Solomon Assefa
	Title	ELECTRICALLY-ACTIVATED PHOTONIC CRYSTAL MICROCAVITY LASER	
	Atty Docket Number		MIT.10307

I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).

11/25/01

Date

Matthew E. Connors Reg. No. 47,259

Signature

Matthew E. Connors
Typed or printed name

This request must be signed in compliance with 37 CFR 1.33(b) and submitted with the application **upon filing**.

Applicant may rescind this nonpublication request at any time. If applicant rescinds a request that an application not be published under 35 U.S.C. 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, the applicant **must** notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. **Failure to do so will result in abandonment of this application (35 U.S.C. 122(b)(2)(B)(iii)).**

Burden Hour Statement: This collection of information is required by 37 CFR 1.213(a). The information is used by the public to request that an application not be published under 35 U.S.C. 122(b) (and the PTO to process that request). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 6 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner of Patents, Washington, DC 20231.